A5047145634- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Renal cell carcinoma treatment
- Urinary and Genital Oncology Studies
- Cancer Genomics and Diagnostics
- Renal and related cancers
- Genital Health and Disease
- Pancreatic and Hepatic Oncology Research
- CAR-T cell therapy research
- Cancer and Skin Lesions
- Metastasis and carcinoma case studies
- Fibroblast Growth Factor Research
- Ferroptosis and cancer prognosis
- Urological Disorders and Treatments
- Multiple and Secondary Primary Cancers
- Esophageal Cancer Research and Treatment
- Nonmelanoma Skin Cancer Studies
- Economic and Financial Impacts of Cancer
- Cancer Diagnosis and Treatment
Hôpital Saint-André
2019-2024
Université de Bordeaux
2022-2024
Centre Hospitalier Universitaire de Bordeaux
2019-2024
Centre Hospitalier Universitaire de Caen
2019
Université de Caen Normandie
2019
Immune checkpoint inhibitors (ICI) have been approved for front-line therapy in metastatic renal cell carcinoma (mRCC). However, progressive disease often occurs and subsequent therapies are needed. ICI rechallenge may be an option, but there is a lack of data regarding efficacy prognostic factors. We assessed factors associated with better outcomes. Patients Methods. This ambispective multicenter study included 45 mRCC patients rechallenged nivolumab ± ipilimumab between 2014 2020. Primary...
In the past decade, therapeutic arsenal for metastatic bladder cancer has expanded considerably, with development of immune checkpoint inhibitors (ICIs), antibody-drug conjugates such as enfortumab vedotin, and anti-fibroblast growth factor receptor agents. Clinical trials evaluating ICIs neoadjuvants, adjuvants, or first- second-line treatments have produced conflicting results. However, first-line strategies been redefined by recent publication results from two clinical trials:...
8 Background: Metastatic squamous cell penile carcinoma (mSCPC) is an orphan disease with a virally induced oncogenesis. PD-L1 expression rate around 60% strong correlation between in the primary tumour and metastases. The first line systemic treatment relies on platinum-based chemotherapies median progression free survival overall 7.5 16 months (mo), respectively. Immunotherapies targeting PD-1/PD-L1 axis are effective other or HPV related cancers. Methods: PULSE national prospective...
TPS487 Background: Treatment of mRCC consists combination either Immune Checkpoint Inhibitor (ICI)-Tyrosine Kinase (TKI) for all IMDC prognosis group, or ICI-ICI intermediate and unfavorable groups. Treatments are maintained until disease progression toxicity a total duration 2 years ICI, in routine. Acceptability feasibility treatment pause the TKI, with no detrimental effect on efficacy were reported prospective STAR trial. The good-risk population is characterized by prolonged survival,...
Anti-PD-(L)1 agent are approved as first- and second-line treatment options in advanced urothelial cancer (UC), but information about long-term survival is scarce. There a need for prognostic factors, these may help the decision-making concerning anti-PD-(L)1 patients with UC. Here, we examined following UC assessed clinical factors their correlation survival.
330 Background: Immune checkpoint inhibitors (ICIs) in combination with another ICI or an antiangiogenic targeted therapy have been approved for frontline metastatic renal cell carcinoma (mRCC). However, progression disease (PD) often occurs and subsequent therapies are needed. Rechallenge of may then be option, but there is a lack data regarding this strategy. Methods: This ambispective multicenter study included patients who received rechallenge Nivolumab (ICI-2) between January 2014...
430 Background: Primary urethral cancer (PUC) is a rare and heterogeneous malignancy. Due to its scarcity, little data are available on the optimal treatment sequence survival, especially in metastatic patients. Methods: Data from patients diagnosed with PUC between 01/01/2000 12/31/2018 were retrospectively collected nine French referral centers. Survival rate estimated Kaplan-Meier method prognostic factors analyzed using Cox proportional hazards model log-rank test. In order increase...
492 Background: Immune checkpoints inhibitors (ICIs) have recently changed therapeutic landscape of la/mUC. Recent studies suggested an improvement response to salvage chemotherapy (CT) after ICIs in several cancer types including urothelial carcinoma. We assumed that efficacy CT rechallenge may be improved compared second-line without previous patients (pts) with Methods: CIMUC is a French multicentric retrospective study all pts la/mUC initiating second or third-line from January 1 st 2015...